WO2018003796A1 - Produit ophtalmique et procédé pour empêcher une baisse de la viscosité - Google Patents

Produit ophtalmique et procédé pour empêcher une baisse de la viscosité Download PDF

Info

Publication number
WO2018003796A1
WO2018003796A1 PCT/JP2017/023572 JP2017023572W WO2018003796A1 WO 2018003796 A1 WO2018003796 A1 WO 2018003796A1 JP 2017023572 W JP2017023572 W JP 2017023572W WO 2018003796 A1 WO2018003796 A1 WO 2018003796A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
salt
enclosure
ophthalmic
hydrochloride
Prior art date
Application number
PCT/JP2017/023572
Other languages
English (en)
Japanese (ja)
Inventor
奥村　隆
香菜 内藤
Original Assignee
ライオン株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ライオン株式会社 filed Critical ライオン株式会社
Priority to JP2018525176A priority Critical patent/JP7040440B2/ja
Priority to KR1020187022405A priority patent/KR102665052B1/ko
Publication of WO2018003796A1 publication Critical patent/WO2018003796A1/fr
Priority to JP2021210334A priority patent/JP7314986B2/ja

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A61K31/125—Camphor; Nuclear substituted derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Definitions

  • the present invention relates to an ophthalmic product in which a decrease in viscosity of a water-soluble polymer compound is suppressed.
  • a method in which a thickening agent such as a polymer compound is blended in order to improve effectiveness and maintain a refreshing feeling, thereby increasing drug retention on the ocular surface.
  • the improvement in retention of the active ingredient on the ocular surface is considered to be particularly beneficial for active ingredients that act on corneal epithelial cells on the ocular surface such as vitamin A.
  • a refreshing agent such as menthol is used.
  • a refreshing component such as vitamin A and menthol is a fat-soluble component, a surfactant is often blended at the same time in order to blend these components into an aqueous eye drop.
  • a method of blending vegetable oil such as sesame oil (Patent Document 1: Japanese Patent Laid-Open No. 2005-206598) or a method of blending castor oil (Patent Document 2: Japanese Patent Laid-Open No. 2005) No. -206599) and a method of adding mannitol or glycerin (Patent Document 3: Japanese Patent Laid-Open No. 11-71478) is known.
  • the decrease in viscosity of the ophthalmic composition blended with the polymer compound is caused by the influence of various blending components, and a surfactant used when blending fat-soluble components such as vitamin A and menthol was added. At that time, a decrease in viscosity is particularly likely to occur, and the above-described method was not sufficient in suppressing the decrease in viscosity.
  • the viscosity of the ophthalmic composition greatly contributes to improving the effectiveness of the drug and the sustainability of the refreshing agent, and also greatly affects the feeling of use resulting from the viscosity. For example, a viscosity that is too high is sticky or sticky, after use. There is a possibility of causing blurring of the field of view. Maintaining the design viscosity of the formulation without changing it is very important in terms of effectiveness and usability in maintaining the quality of the ophthalmic composition. Such a high viscosity stabilization method. Was desired.
  • the present invention tends to cause a decrease in viscosity particularly when the polymer compound is added. It has been found that this is particularly remarkable when oxyethylene polyoxypropylene glycol is used. It aims at providing the technique which suppresses such a viscosity fall.
  • the present inventors have formulated specific components and used specific packaging means in an ophthalmic composition containing a polymer compound, a surfactant, and a fat-soluble component.
  • a high viscosity reduction suppressing effect is exhibited.
  • the ophthalmic composition provided by the present invention exhibits a high retention during instillation and is excellent in a moist feeling sustaining effect.
  • the present invention provides the following. [1].
  • A a water-soluble polymer compound,
  • B polyoxyethylene polyoxypropylene glycol,
  • C one or more components selected from vitamin A, vitamin E, dibutylhydroxytoluene and a refreshing agent, and
  • D one or more components selected from the group consisting of (D-1) and (D-2) below (D-1) trometamol, propylene glycol (D-2) ethylenediamineacetic acid derivative, salt thereof, tetrahydrozoline hydrochloride, epsilon aminocaproic acid, allantoin, glycyrrhizic acid, salt thereof, chlorpheniramine maleate, pyridoxine hydrochloride, panthenol, An ophthalmic composition containing chondroitin sulfate, a salt thereof, neostigmine methyl sulfate, diphenhydramine hydrochloride, cyanocobalamin, sodium chloride, aspartic
  • A a water-soluble polymer compound
  • B polyoxyethylene polyoxypropylene glycol
  • C an ophthalmic composition containing one or more fat-soluble components selected from vitamin A, vitamin E, dibutylhydroxytoluene and a refreshing agent, a container filled with the ophthalmic composition, and the container
  • an ophthalmic product having an enclosure for packaging, (1) Inert gas injection into the enclosure, (2) Enclosure of oxygen absorber into the enclosure, (3) Either an oxygen-absorbing vessel or (4) an enclosure with oxygen-absorbing capability
  • D (D) (D-1) and (D-2) below (D-1) trometamol, propylene glycol (D-2) ethylenediamineacetic acid derivative, salt thereof, tetrahydrozoline hydrochloride, epsilon aminocaproic acid, allantoin, glycyrrhizic acid, salt thereof, chlorpheniramine maleate, pyridoxine hydrochloride, panthenol, Chondroitin,
  • a high viscosity reduction inhibitory effect can be obtained in a composition containing a polymer compound, a surfactant and a fat-soluble component.
  • water-soluble polymer compounds include cellulose polymer compounds such as hydroxypropylmethylcellulose (hypromellose), methylcellulose, and hydroxyethylcellulose; polyvinyl polymer compounds such as polyvinylpyrrolidone (povidone) and polyvinyl alcohol; hyaluronic acid and salts thereof; carboxy A vinyl polymer etc. are mentioned, It can use individually by 1 type or in combination of 2 or more types. By blending such components, it is possible to impart viscosity to the composition, improve the retention of the blended active ingredients on the ocular surface, and prevent drying of the ocular surface by retaining on the ocular surface. it can.
  • cellulose polymer compounds such as hydroxypropylmethylcellulose (hypromellose), methylcellulose, and hydroxyethylcellulose
  • polyvinyl polymer compounds such as polyvinylpyrrolidone (povidone) and polyvinyl alcohol
  • hyaluronic acid and salts thereof carboxy A vinyl polymer etc.
  • hydroxypropylmethylcellulose methylcellulose, hydroxyethylcellulose, polyvinylpyrrolidone, carboxyvinyl polymer, hyaluronic acid and salts thereof are preferable, and hydroxypropylmethylcellulose is preferable.
  • the water-soluble polymer compound is a polymer compound that can be dissolved in an aqueous solution, and its weight average molecular weight is preferably 5,000 to 5,000,000, more preferably 10,000 to 2,500,000. preferable.
  • the measurement of a weight average molecular weight can be calculated
  • the compounding amount of the component (A) is preferably 0.01 to 10% (W / V% (mass / volume%, g / 100 mL or less)) in the composition, and more preferably 0.05 to 3%.
  • the content is preferably 0.05 to 5%, more preferably 0.1 to 3%, still more preferably 0.1 to 0.5%.
  • methylcellulose is blended, it is preferably 0.05 to 5% in the composition, more preferably 0.1 to 3%, and still more preferably 0.1 to 1%.
  • the content is preferably 0.05 to 5%, more preferably 0.1 to 3%, and still more preferably 0.1 to 1%.
  • the content is preferably 0.01 to 10%, more preferably 0.05 to 5%, and still more preferably 0.05 to 3%.
  • the content is preferably 0.01 to 5%, more preferably 0.05 to 3%, still more preferably 0.1 to 1%.
  • the content is preferably 0.01 to 3%, more preferably 0.01 to 1%, still more preferably 0.02 to 1%.
  • polyoxyethylene polyoxypropylene glycol polyoxyethylene (200) polyoxypropylene (70) glycol, polyoxyethylene (120) polyoxypropylene (40) glycol, polyoxyethylene (160) polyoxypropylene (30) Glycol, polyoxyethylene (42) polyoxypropylene (67) glycol, polyoxyethylene (54) polyoxypropylene (39) glycol, polyoxyethylene (20) polyoxypropylene (20) glycol and the like alone Or two or more can be used in appropriate combination.
  • polyoxyethylene (200) polyoxypropylene (70) glycol is preferable.
  • the blending amount of the component (B) is preferably 0.1 to 10%, more preferably 0.1 to 5%, further preferably 0.4 to 3% in the composition.
  • (C) component etc. can be mix
  • Component (C) It is 1 or more types of components chosen from vitamin A, vitamin E, dibutylhydroxytoluene, and a refreshing agent, This fat-soluble component can be used individually by 1 type or in combination of 2 or more types.
  • Vitamin A has a corneal wound healing effect and the like, and in addition to vitamin A itself, vitamin A-containing mixtures such as vitamin A oil, vitamin A derivatives such as vitamin A fatty acid esters and the like can be mentioned. Specific examples include retinol palmitate, retinol acetate, retinol, retinoic acid, and retinoid. Of these, retinol palmitate is preferred.
  • the blending amount is preferably 5,000 to 500,000 international units (IU) in 100 mL of the ophthalmic composition, more preferably 10,000 to 100,000 international units (IU). More preferably, 5,000-75,000 international units (IU).
  • IU international units
  • a corneal wound healing effect due to vitamin A can be expected at a lower limit value or more, and vitamin A stability can be further obtained at an upper limit value or less.
  • vitamin E examples include tocopherol acetate (dl- ⁇ -tocopherol acetate, d- ⁇ -tocopherol acetate (vitamin E)), tocopherol succinate, and derivatives thereof. Of these, d- ⁇ -tocopherol acetate is preferred.
  • the blending amount is preferably 0.005 to 0.5%, more preferably 0.01 to 0.1% in the ophthalmic composition.
  • the effect and stability can be further improved within the above range.
  • the blending amount is preferably 0.001 to 0.05%, more preferably 0.003 to 0.01% in the ophthalmic composition.
  • the effect and stability can be further improved within the above range.
  • Refreshing agents include menthol, camphor, cool mint, geraniol, mint water, borneol, eucalyptus oil, fennel oil, rose oil, bergamot oil, peppermint oil, spearmint oil, linalool, anethole, eugenol, cineol, N-ethyl- and p-menthane-carboxamide.
  • menthol is preferable.
  • the blending amount is preferably 0.001 to 0.5%, more preferably 0.005 to 0.3% in the ophthalmic composition. Within the above range, an effect and a good refreshing feeling upon instillation can be obtained.
  • [(D) component] (D) One or more selected from the group consisting of (D-1) and (D-2) below. (D) By mix
  • ethylenediamineacetic acid derivatives or salts thereof examples include edetic acid (ethylenediaminetetraacetic acid), ethylenediaminediacetic acid, diethylenetriaminepentaacetic acid, N- (2-hydroxyethyl) ethylenediaminetriacetic acid, sodium edetate (ethylenediaminetetraacetic acid sodium), ethylenediamine Examples thereof include disodium tetraacetate and hydrates thereof.
  • Examples of glycyrrhizic acid or a salt thereof include glycyrrhizic acid, dipotassium glycyrrhizinate, disodium glycyrrhizinate, diammonium glycyrrhizinate, and the like.
  • Examples of chondroitin sulfate or a salt thereof include chondroitin sulfate, chondroitin polysulfate, sodium chondroitin sulfate, and the like.
  • Aspartic acid or a salt thereof includes, for example, sodium L-aspartate, potassium L-aspartate, magnesium L-aspartate, calcium L-aspartate, magnesium L-aspartate and potassium (L-aspartate and L- And an equivalent mixture with potassium aspartate).
  • the above can be used singly or in appropriate combination of two or more, among which trometamol, propylene glycol, allantoin and panthenol are preferable. Further, when two or more types are combined, it is preferably one or more types from the (D-1) group and one or more types from the (D-2) group.
  • the blending amount of the component (D) is preferably 0.001 to 10%, more preferably 0.01 to 5%, and still more preferably 0.01 to 3% in the ophthalmic composition. By setting it as this range, the viscosity fall by using the said (A) and (B) component together can be suppressed more.
  • Trometamol is 0.01 to 10%, more preferably 0.1 to 5%.
  • Propylene glycol is 0.01 to 10%, more preferably 0.1 to 5%.
  • the ethylenediamineacetic acid derivative or a salt thereof is 0.001 to 2%, more preferably 0.01 to 1.5%.
  • Tetrahydrozoline hydrochloride is 0.001 to 2%, more preferably 0.01 to 1%.
  • Epsilon aminocaproic acid is 0.01 to 10%, more preferably 0.1 to 5%.
  • Allantoin is 0.001 to 5%, more preferably 0.01 to 1%.
  • Glycyrrhizic acid or a salt thereof is 0.001 to 5%, more preferably 0.01 to 1%.
  • Chlorpheniramine maleate is 0.001-1%, more preferably 0.003-0.1%.
  • Pyridoxine hydrochloride is 0.001 to 2%, more preferably 0.01 to 1%.
  • Panthenol is 0.001 to 2%, more preferably 0.01 to 1%.
  • Chondroitin sulfate or a salt thereof is 0.001 to 5%, more preferably 0.01 to 2%.
  • Neostigmine methyl sulfate is 0.0001 to 0.05%, more preferably 0.001 to 0.01%.
  • Diphenhydramine hydrochloride is 0.001 to 0.5%, more preferably 0.01 to 0.1%.
  • Cyanocobalamin is 0.001 to 0.5%, more preferably 0.005 to 0.05%.
  • Sodium chloride is 0.01 to 5%, more preferably 0.05 to 1%.
  • Aspartic acid or a salt thereof is 0.01 to 10%, more preferably 0.05 to 5%.
  • Aminoethylsulfonic acid is 0.01 to 5%, more preferably 0.05 to 3%.
  • ophthalmic composition of the present invention various components used in the ophthalmic composition can be blended as necessary within a range not impairing the effects of the present invention.
  • Preferred compounding ingredients include drugs, buffers, stabilizers, tonicity agents, antioxidants, preservatives and the like. These can be used individually by 1 type or in combination of 2 or more types, and can mix
  • Examples of the drug include a decongestant component other than the component (D), an eye muscle modulator component, an anti-inflammatory component or an astringent component, an antihistamine component or an antiallergic component, vitamins, amino acids, antibacterial component Or a bactericide component, saccharides, polysaccharides other than (A) component or derivatives thereof, polyhydric alcohol, local anesthetic components, steroid components, glaucoma treatment components, cataract treatment components, mydriasis components and the like. Specific examples are shown below.
  • Decongestant ⁇ -adrenergic agonist, for example, imidazoline derivatives (naphazoline, tetrahydrozoline, etc.), ⁇ -phenylethylamine derivatives (phenylephrine, epinephrine, ephedrine, methylephedrine, etc.), and their pharmaceutically or physiologically acceptable Salts (for example, inorganic acid salts such as naphazoline hydrochloride, naphazoline nitrate, tetrahydrozoline nitrate, phenylephrine hydrochloride, epinephrine hydrochloride, ephedrine hydrochloride, and methylephedrine hydrochloride; organic acid salts such as epinephrine hydrogen tartrate) and the like.
  • imidazoline derivatives naphazoline, tetrahydrozoline, etc.
  • ⁇ -phenylethylamine derivatives phenyleph
  • O Eye muscle modulator component cholinesterase inhibitor having an active center similar to acetylcholine, tropicamide, atropine sulfate and the like.
  • Anti-inflammatory or astringent components pranoprofen, celecoxib, rofecoxib, indomethacin, diclofenac, diclofenac sodium, piroxicam, meloxicam, aspirin, mefenamic acid, indomethacin farnesyl, acemetacin, ibuprofen, thiaprofenic acid, loxoprofen sodium, zinc thiaramide hydrochloride
  • salts for example, zinc sulfate, zinc chloride, zinc lactate, etc.
  • lysozyme lysozyme hydrochloride
  • methyl salicylate sodium azulene sulfonate
  • berberine chloride berberine sulfate and the like.
  • Antihistamine component or antiallergic component for example, ketotifen, acitazanolast, levocabastine, cromoglycic acid, tranilast, ibudilast, amlexanox, pemirolast and pharmaceutically or physiologically acceptable salts thereof (ketotifen fumarate, cromoglyc Acid sodium etc.).
  • Vitamins examples include flavin adenine dinucleotide sodium (active vitamin B 2 ), ascorbic acid and the like.
  • Amino acids for example, leucine, isoleucine, valine, methionine, threonine, alanine, phenylalanine, tryptophan, lysine, glycine, serine, proline, tyrosine, cysteine, histidine, ornithine, hydroxyproline, hydroxylysine, glycylglycine, ⁇ -amino
  • Examples include butyric acid, glutamic acid or a salt thereof (for example, cysteine hydrochloride and the like).
  • Antibacterial component or bactericidal component sulfonamides (for example, sulfamethoxazole, sulfisoxazole, sulfisomidine and pharmacologically acceptable salts (sulfamethoxazole sodium, sulfisomidine sodium, etc.) ), Etc.), acrinol, alkylpolyaminoethylglycine, new quinolone (lomefloxacin, levofloxacin, ciprofloxacin, ofloxacin, norfloxacin, ciprofloxacin hydrochloride, etc.), berberine or a salt thereof (eg, berberine chloride, berberine sulfate) ), ⁇ -lactam antibiotics (sulbenicillin, cefmenoxime, etc.), aminoglycoside antibiotics (kanamycin, gentamicin, tobramycin, sisomycin, dibekac
  • antiviral drugs doxuridine, acyclovir, adenine arabinoside, ganciclovir, foscarnet, valacyclovir, trifluorothymidine, cidophobia, carbocyclic oxetanocin G, etc.
  • antifungal drugs pimaricin, fluconazole, itraconazole, miconazole, Flucytosine, amphotericin B, etc.
  • saccharide examples include lactulose, raffinose, pullulan, glucose, maltose, trehalose, sucrose, cyclodextrin, xylitol, mannitol, sorbitol and the like.
  • Polysaccharides or derivatives thereof gum arabic, karaya gum, xanthan gum, carob gum, guar gum, guaiac gum, quince seed, dalman gum, tragacanth, benzoin gum, locust bean gum, casein, agar, alginic acid, dextrin, dextran, carrageenan, gelatin, collagen, Examples include pectin, starch, polygalacturonic acid (alginic acid), chitin and derivatives thereof, chitosan and derivatives thereof, and elastin.
  • Polyhydric alcohol glycerin, butylene glycol, polyethylene glycol and the like.
  • Local anesthetic ingredients chlorobutanol, lidocaine, oxybuprocaine, dipcaine, procaine, ethyl aminobenzoate, meprilucaine, mepivacaine, bupivacaine, cocaine and their salts (lidocaine hydrochloride, oxybuprocaine hydrochloride, etc.) .
  • Steroid component Hydrocortisone, prednisolone, cortisol, methylprednisolone, triamcinolone, parameterzone, betamethasone and their salts.
  • Glaucoma treatment ingredients distigmine bromide, timolol maleate, carteolol hydrochloride, betaxolol hydrochloride, latanoprost, isopropylunoprostone, dipivefrine hydrochloride, apraclonidine hydrochloride, pilocarpine hydrochloride, carbachol, dorzolamide hydrochloride, acetazolamide, metazolamide Etc.
  • pirenoxine pirenoxine
  • glutathione salivary gland hormone
  • thiopronin Dihydro azapdntacnd disulfonatd and salts thereof (for example, sodium 5,12-dihydrodacnddisdisfond etc.) and the like.
  • Mydriatic component cyclopentrate hydrochloride, tropicamide and the like.
  • an effective appropriate amount of each drug can be selected as the compounding amount.
  • 0.001 in the ophthalmic composition It is preferably in the range of ⁇ 5%.
  • the buffer for example, citric acid, sodium citrate, boric acid, borax, phosphoric acid, sodium hydrogen phosphate, sodium dihydrogen phosphate, glacial acetic acid, and sodium hydrogen carbonate are preferably used.
  • the blending amount is preferably in the range of 0.003 to 4% in the composition.
  • the stabilizer examples include ⁇ -cyclodextrin, ⁇ -cyclodextrin, ⁇ -cyclodextrin and the like.
  • the blending amount is preferably in the range of 0.003 to 2% in the composition.
  • the isotonic agent examples include potassium chloride, calcium chloride, magnesium chloride, potassium acetate, sodium acetate, sodium carbonate, magnesium sulfate, disodium hydrogen phosphate, sodium dihydrogen phosphate, sodium hydrogen sulfite and the like.
  • the blending amount is preferably in the range of 0.001 to 3% in the composition.
  • antioxidants examples include butylhydroxyanisole (BHA), hydroquinone, propyl gallate, sodium bisulfite and the like.
  • BHA butylhydroxyanisole
  • hydroquinone hydroquinone
  • propyl gallate sodium bisulfite
  • the blending amount is preferably in the range of 0.001 to 1% in the composition.
  • preservatives examples include parabens such as benzalkonium chloride, benzethonium chloride, chlorhexidine gluconate, sorbic acid, potassium sorbate, chlorobutanol, and paraoxybenzoic acid ester, polydronium chloride, alkyldiaminoethylglycine hydrochloride, sodium benzoate And polyhexamethylene biguanide.
  • the blending amount thereof is preferably in the range of 0.0001 to 0.5% in the composition, and more preferably in the range of 0.001 to 0.5%.
  • the ophthalmic composition of the present invention can be produced by a known production method with the balance being water.
  • each of the above components can be obtained by dissolving in sterilized purified water, water such as ion exchange water, or a mixed solvent with water.
  • the fat-soluble component such as component (C) is dissolved in (B) polyoxyethylene polyoxypropylene glycol, and then charged into a high-temperature (70 to 95 ° C.) aqueous solution in which other aqueous components are dissolved, and then the pH is adjusted.
  • the osmotic pressure and the like can be appropriately adjusted with a pH adjusting agent or an isotonizing agent.
  • pH regulators include hydrochloric acid, sulfuric acid, phosphoric acid, sodium hydroxide, potassium hydroxide, magnesium hydroxide, calcium hydroxide and the like.
  • the pH (20 ° C.) of the ophthalmic composition of the present invention is preferably 3.5 to 8.0, more preferably 4.5 to 7.7, and still more preferably 5.5 to 7.5. If the pH is too low or too high, the feeling of irritation can be strong.
  • the pH is measured at 20 ° C. using a pH osmometer (HSMO-1, Toa DKK Corporation).
  • As the pH adjuster sodium hydroxide, potassium hydroxide, hydrochloric acid and the like are preferable.
  • the ophthalmic composition of the present invention is preferably a liquid, and the viscosity at 20 ° C. is preferably 1 to 400 mPa ⁇ s, more preferably 1 to 100 mPa ⁇ s, still more preferably 1 to 60 mPa ⁇ s, and 1 to 50 mPa ⁇ s, 1 to 20 mPa ⁇ s is particularly preferable.
  • the viscosity is measured using a B-type viscometer.
  • the present invention is an ophthalmic product comprising an ophthalmic composition, a container filled with the ophthalmic composition, and an enclosure for packaging the container, wherein the oxygen concentration in the ophthalmic composition is reduced.
  • Means include (1) injecting inert gas into the enclosure, (2) bundling of oxygen absorbent into the enclosure, (3) container having oxygen absorption capacity, or (4) enclosure having oxygen absorption capacity. Etc. By such means, a decrease in viscosity due to the combined use of the above components (A) and (B) can be further suppressed.
  • the enclosure is preferably capable of sealing the container.
  • the container is preferably a plastic container, and materials such as polyethylene, polyethylene terephthalate, polypropylene, polybutylene, polycarbonate, polyarylate, vinyl chloride, or a composite of these materials can be used. Polyethylene terephthalate is particularly preferable.
  • the oxygen permeability coefficient of the container is preferably 10 cc / m 2 ⁇ 24 hr ⁇ atm or more.
  • the envelope examples include polyethylene, polyethylene terephthalate, polypropylene, polybutylene, polycarbonate, polyester, nylon, cellophane, polyvinyl chloride film, aluminum foil, polyvinyl alcohol / polyamide film deposited with aluminum, and polyvinylidene chloride. A composite or multilayer film of these, such as a film or a laminate film, may be mentioned.
  • the oxygen permeability coefficient of the envelope is preferably 10 cc / m 2 ⁇ 24 hr ⁇ atm or less (that is, 0 to 10 cc / m 2 ⁇ 24 hr ⁇ atm).
  • the inert gas includes nitrogen, helium, neon, argon, and the like. Of these, nitrogen gas is preferred.
  • the concentration of the inert gas is preferably 50% by volume or more, more preferably 80% by volume or more, and further preferably 90% by volume or more in the space volume formed between the enclosure and the plastic container.
  • An upper limit is not specifically limited, It is 100 volume% or less. In order to achieve such a concentration, the space formed between the enclosure and the plastic container may be replaced with an inert gas.
  • Container having oxygen absorbing ability An oxyblock manufactured by Toyo Seikan Co., Ltd., an oxyvanish manufactured by Mitsubishi Gas Chemical Co., Ltd., etc.
  • Oxycatch (registered trademark) ICA manufactured by Kyodo Printing Co., Ltd., Cryovac (registered trademark) OS film manufactured by Shield Air, Histar O2 manufactured by Star Plastic Industry Co., Ltd. Ageless Omak manufactured by Mitsubishi Gas Chemical Co., Ltd., Oxydec manufactured by Toyo Seikan Co., Ltd., etc. can be used.
  • the present invention (A) a water-soluble polymer compound, (B) polyoxyethylene polyoxypropylene glycol, (C) an ophthalmic composition containing one or more fat-soluble components selected from vitamin A, vitamin E, dibutylhydroxytoluene and a refreshing agent, a container filled with the ophthalmic composition, and the container
  • an ophthalmic product having an enclosure for packaging, (1) Inert gas injection into the enclosure, (2) Enclosure of oxygen absorber into the enclosure, (3) Either an oxygen-absorbing vessel or (4) an enclosure with oxygen-absorbing capability Using means, (D) (D-1) and (D-2) below (D-1) trometamol, propylene glycol (D-2) ethylenediamineacetic acid derivative, salt thereof, tetrahydrozoline hydrochloride, epsilon aminocaproic acid, allantoin, glycyrrhizic acid, salt thereof, chlorpheniramine maleate, pyridoxine hydrochloride, pantheno
  • the present invention provides: (A) a water-soluble polymer compound, (B) polyoxyethylene polyoxypropylene glycol, (C) an ophthalmic composition containing one or more fat-soluble components selected from vitamin A, vitamin E, dibutylhydroxytoluene and a refreshing agent, a container filled with the ophthalmic composition, and the container (1) Inert gas injection into the enclosure, (2) Enclosure of oxygen absorbent in the enclosure, (3) Container having oxygen absorption capacity, or (4) Oxygen absorption In an ophthalmic product using any means of an enclosure having a function, in the ophthalmic composition, (D) (D-1) and (D-2) below (D-1) trometamol, propylene glycol (D-2) ethylenediamineacetic acid derivative or salt thereof, tetrahydrozoline hydrochloride, epsilon aminocaproic acid, allantoin, glycyrrhizic acid or salt thereof, chlorpheniramine maleate, pyridoxine
  • Examples and Comparative Examples The ophthalmic composition having the composition shown in the following table is dissolved in a polyoxyethylene polyoxypropylene glycol after dissolving a fat-soluble component and then poured into a high-temperature (70 to 95 ° C.) aqueous solution in which other aqueous components are dissolved. Ophthalmic compositions having the compositions shown in the table were produced. The obtained ophthalmic composition was filled in an eye drop container made of polyethylene terephthalate, and then a film package containing an oxygen absorbent (AGELESS: Z-20PK manufactured by Mitsubishi Gas Chemical Co., Ltd.) was applied.
  • AGELESS Z-20PK manufactured by Mitsubishi Gas Chemical Co., Ltd.
  • the viscosity before storage (20 ° C.) was measured with a B-type viscometer (digital viscometer DV2T, manufactured by Eihiro Seiki Co., Ltd.) and stored for 2 months in an environment of 50 ° C. and 75% RH. After storage, the eye drops were returned to room temperature (20 ° C.) and measured in the same manner as before storage. Based on the following formula, the viscosity retention rate (%) of each example was determined from the obtained viscosity, and the viscosity retention rate enhancement effect (%) with respect to Comparative Example 1 was calculated.
  • the “comparative examples described in each table” refers to a comparative example not including the component (D) corresponding to each example.
  • the film packaging is made by Ageless Omak manufactured by Mitsubishi Gas Chemical Co., Ltd.
  • the composition was excellent in viscosity stability. These ophthalmic products having such effects are excellent in the viscosity stability of the composition, and can maintain the retention effect on the ocular surface such as active ingredients and cooling agents.
  • the viscosity reduction of the ophthalmic composition due to the combination of the components (A) and (B) can be reduced by the addition of the above means and the component (D), or the component (D). It can suppress by addition and can maintain the retention effect in the ocular surface, such as an active ingredient of (C) component, a refreshing agent.
  • Hydroxypropyl methylcellulose Hypromellose (60SH-4000), Metrolose 60SH-4000, JP, Shin-Etsu Chemical Co., Ltd., weight average molecular weight 300,000 (g / mol)
  • Polyvinylpyrrolidone Kollidon 90F, JP, BASF Corp., weight average molecular weight 1 million (g / mol) Hydroxyethyl cellulose: HEC CF-V, supplementary regulations, Sumitomo Seika Co., Ltd., weight average molecular weight 900,000 (g / mol) Methylcellulose: Metrows SM-400, JP, Shin-Etsu Chemical Co., Ltd.
  • Sodium hyaluronate Sodium biohyaluronate, Shiseido carboxyvinyl polymer: Carbopol (registered trademark) 971PNF, Supplementary regulations, Lubrizol polyoxyethylene (200) Polyoxypropylene (70) glycol: Unilube 70DP-950B, Supplementary regulations, Japan Oil Co., Ltd. or Lutrol F127, Addendum, BASF Co., Ltd.
  • Retinol palmitic acid ester a Japanese pharmacy product (Retinol palmitic acid ester, DSM Nutrition Japan Co., Ltd.)
  • D- ⁇ -Tocopherol acetate an extra-regular product, (RIKEN E Acetate ⁇ , Riken Vitamin Co., Ltd.)
  • Dibutylhydroxytoluene Supplementary product, (Dibutylhydroxytoluene, Wako Pure Chemical Industries, Ltd.)
  • component (D) various raw materials conforming to official standards (Japanese Pharmacopoeia, Japanese Pharmacopoeia Pharmaceutical Standards, Pharmaceutical Additive Standards, etc.) standards were used.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Ophthalmology & Optometry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne un produit ophtalmique comprenant : une composition ophtalmique qui comprend (A) un composé polymère soluble dans l'eau, (B) du polyoxyéthylène polyoxypropylène glycol, (C) au moins un composant choisi parmi la vitamine A, la vitamine E, le dibutylhydroxytoluène et un agent réfrigérant, et (D) au moins un composant choisi dans le groupe constitué par (D-1) le trométamol et le propylène glycol et (D-2) un dérivé d'acide éthylènediamineacétique ou un sel de celui-ci, le chlorhydrate de tétrahydrozoline, l'acide epsilon-aminocaproïque, l'allantoïne, l'acide glycyrrhizique ou un sel de celui-ci, le maléate de chlorphényramine, le chlorhydrate de pyridoxine, le panthénol, le sulfate de chondroïtine ou un sel de celui-ci, le méthylsulfate de néostigmine, le chlorhydrate de diphénhydramine, la cyanocobalamine, le chlorure de sodium, l'acide aspartique ou un sel de celui-ci et l'acide aminoéthylsulfonique ; un récipient rempli de la composition ophtalmique ; et un corps d'emballage pour emballer le récipient.
PCT/JP2017/023572 2016-06-30 2017-06-27 Produit ophtalmique et procédé pour empêcher une baisse de la viscosité WO2018003796A1 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2018525176A JP7040440B2 (ja) 2016-06-30 2017-06-27 眼科用製品及び粘度低下抑制方法
KR1020187022405A KR102665052B1 (ko) 2016-06-30 2017-06-27 안과용 제품 및 점도 저하 억제 방법
JP2021210334A JP7314986B2 (ja) 2016-06-30 2021-12-24 眼科用製品及び粘度低下抑制方法

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2016-130614 2016-06-30
JP2016130614 2016-06-30

Publications (1)

Publication Number Publication Date
WO2018003796A1 true WO2018003796A1 (fr) 2018-01-04

Family

ID=60787155

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2017/023572 WO2018003796A1 (fr) 2016-06-30 2017-06-27 Produit ophtalmique et procédé pour empêcher une baisse de la viscosité

Country Status (4)

Country Link
JP (3) JP7040440B2 (fr)
KR (1) KR102665052B1 (fr)
TW (1) TW201801719A (fr)
WO (1) WO2018003796A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019218270A (ja) * 2018-06-15 2019-12-26 ライオン株式会社 眼科用組成物及び消泡促進方法
JP7379913B2 (ja) 2019-08-07 2023-11-15 ライオン株式会社 ソフトコンタクトレンズ用眼科組成物及び眼科用製品

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004123634A (ja) * 2002-10-03 2004-04-22 Lion Corp 眼科用組成物
WO2010150812A1 (fr) * 2009-06-25 2010-12-29 ライオン株式会社 Composition ophtalmique et méthode de prévention de la nébulosité/précipitation
WO2011001951A1 (fr) * 2009-06-30 2011-01-06 ライオン株式会社 Composition ophtalmique
JP2011021002A (ja) * 2009-06-16 2011-02-03 Lion Corp 眼科用組成物
JP2013237638A (ja) * 2012-05-15 2013-11-28 Lion Corp 眼科組成物
JP2015101582A (ja) * 2013-11-28 2015-06-04 ライオン株式会社 眼科用組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH1171478A (ja) 1997-08-29 1999-03-16 Santen Pharmaceut Co Ltd 粘度低下防止方法
JP5382972B2 (ja) 2003-12-26 2014-01-08 ロート製薬株式会社 粘度低下が防止された組成物
JP5382973B2 (ja) 2003-12-26 2014-01-08 ロート製薬株式会社 粘度低下が防止された組成物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004123634A (ja) * 2002-10-03 2004-04-22 Lion Corp 眼科用組成物
JP2011021002A (ja) * 2009-06-16 2011-02-03 Lion Corp 眼科用組成物
WO2010150812A1 (fr) * 2009-06-25 2010-12-29 ライオン株式会社 Composition ophtalmique et méthode de prévention de la nébulosité/précipitation
WO2011001951A1 (fr) * 2009-06-30 2011-01-06 ライオン株式会社 Composition ophtalmique
JP2013237638A (ja) * 2012-05-15 2013-11-28 Lion Corp 眼科組成物
JP2015101582A (ja) * 2013-11-28 2015-06-04 ライオン株式会社 眼科用組成物

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019218270A (ja) * 2018-06-15 2019-12-26 ライオン株式会社 眼科用組成物及び消泡促進方法
JP7102964B2 (ja) 2018-06-15 2022-07-20 ライオン株式会社 眼科用組成物及び消泡促進方法
JP7379913B2 (ja) 2019-08-07 2023-11-15 ライオン株式会社 ソフトコンタクトレンズ用眼科組成物及び眼科用製品

Also Published As

Publication number Publication date
JPWO2018003796A1 (ja) 2019-04-18
JP7314986B2 (ja) 2023-07-26
JP2022031430A (ja) 2022-02-18
TW201801719A (zh) 2018-01-16
JP2023108014A (ja) 2023-08-03
KR20190025810A (ko) 2019-03-12
KR102665052B1 (ko) 2024-05-17
JP7040440B2 (ja) 2022-03-23

Similar Documents

Publication Publication Date Title
JP7120018B2 (ja) 眼科用製品及び粘度低下抑制方法
JP5549669B2 (ja) 眼科用組成物、ドライアイ治療剤及びビタミンａの安定化方法
JP7314986B2 (ja) 眼科用製品及び粘度低下抑制方法
JP6260230B2 (ja) 眼科用組成物
JP2011021002A (ja) 眼科用組成物
JP5729109B2 (ja) ソフトコンタクトレンズ用眼科組成物
JP2024061871A (ja) 眼科組成物
JP2005343894A (ja) 抗菌点眼剤
JP2010204597A (ja) ソフトコンタクトレンズ用組成物及びソフトコンタクトレンズへの吸着抑制方法
WO2018225729A1 (fr) Composition ophtalmique pour lentilles de contact souples et procédé de prévention de la séparation de la vitamine a
JP5083502B2 (ja) 眼科用組成物
JP7380772B2 (ja) 眼科用製品及びマスキング方法
JP4524559B2 (ja) 眼科用組成物及びビタミンａ類の安定化方法
JP6267394B1 (ja) 水溶性粘稠化剤を含有する医薬組成物
JP2009079032A (ja) 眼科用組成物及びジフェンヒドラミンの安定化方法
JP7379913B2 (ja) ソフトコンタクトレンズ用眼科組成物及び眼科用製品
JP2019006756A (ja) 水溶性粘稠化剤を含有する医薬組成物
WO2024135344A1 (fr) Produit ophtalmique

Legal Events

Date Code Title Description
ENP Entry into the national phase

Ref document number: 20187022405

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018525176

Country of ref document: JP

Kind code of ref document: A

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17820150

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17820150

Country of ref document: EP

Kind code of ref document: A1